Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
Investors shouldn't count out Pfizer in the GLP-1 market just yet.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
